摘要
目的了解川东北地区梅毒患者感染HIV、HBV或HCV情况,为制定梅毒防控措施提供可靠依据。方法收集我院门诊病人梅毒特异性抗体筛查阳性血清410份,其中特异性IgM抗体阳性110份,运用酶联免疫吸附试验和化学发光法对患者血清进行Anti-HIV、HBV血清学试验5项和Anti-HCV检测。同时以来我院进行HBV体检者(n=1303)作为非梅毒感染对照组,并回顾性分析HBV检测结果。结果梅毒患者HIV感染率为0.48%(95%CI 0.00%~1.16%);HCV感染率为2.44%(95%CI 0.94%~3.92%);HBV感染率为10.24%(95%CI 7.31%~13.17%),其中HBeAg阳性率为26.19%。对照组HBV感染率7.90%(95%CI 6.44%~9.36%),其中HBeAg阳性率为6.79%(7/103),梅毒感染组HBeAg阳性率显著高于对照组(P=0.001)。梅毒特异性IgM抗体阳性人群与阴性人群之间HBV和HCV感染率无统计学差异(P>0.05)。结论梅毒患者感染HBV和HCV情况与梅毒感染阶段无关。梅毒患者感染HIV、HBV或HCV水平较高,应加强对其的干预力度,更好地控制HIV、HBV和HCV的传播。
Aim To investigate the seroprevalence of HBV,HCV and HIV infections among syphilis patients in northeast Sichuan Province. Methods There 110 serum samples positive for syphilis were collected and then the levels of anti-HIV,HBV and Anti-HCV were detected by chemilumineseent microparticle immunoassay (CMIA) and enzymelinked immunosorbent assay (ELISA). There results were compared with 1303 serum samples from non-syphilis controls. Results The seroprevalence of HIV,HCV and HBV were 0.48%(95%CI 0.00%-1.16%),2.44%(95%CI 0.94%-3.92%) and 10.24%(95%CI 7.31%-13.17%),respectively in syphilis patients. HBeAg positive rate was 26.19% in HBV infected patients. The syphilis-HCV-HBV co-infection rate was 0.48%(95%CI 0.00%-1.16%). In the control group,7.90%(95%CI 6.44%-9.36% ) were infected with HBV,6.79% HBV infected patients were positive for HBeAg . HBeAg positive rate increased significantly (P=0.001) in syphilis infected patients as compared with the control group, No difference were observed in HBV and HCV infection between the syphilis specific IgM antibody positive groups and negative group(P〉0.05), Conclusion The phase of syphilis patients is not associated with HBV and HCV infections. The infection rate of syphilis patients with HIV, HBV and HCV is high, thus effective preventive measures be taken to control the spread the co-infection of syphilis with HIV, HBV and HCV.
出处
《中国热带医学》
CAS
2011年第7期842-843,共2页
China Tropical Medicine
关键词
梅毒HBV
HCV
HIV
合并感染
Syphilis
Hepatitis B virus
Hepatitis C virus
Human immunodeficieney virus
Co-infection